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Chronic morphine administration shifts delta-opioid receptors (DORs) from the cytoplasm to the plasma membrane. Given
that microinjection of morphine into the PAG produces antinociception, it is hypothesized that the movement of DORs to the
membrane will allow antinociception to the DOR agonist deltorphin II as a way to compensate for morphine tolerance. Tolerance
was induced by twice daily injections of morphine (5, 10, or 20mg/kg, subcutaneous) for 3.5 days. Microinjection of deltorphin
into the vPAG 6 hours after the last morphine injection produced a mild antinociception that did not vary in a consistent manner
across morphine pretreatment doses or nociceptive tests. In contrast, deltorphin caused a decrease in activity in morphine tolerant
rats that was associated with lying in the cage. The decrease in activity and change in behavior indicate that chronic morphine
administration alters DORs in the vPAG. However, activation of these receptors does not appear to compensate for the decrease in
antinociception caused by morphine tolerance.
Copyright © 2009 Michael M. Morgan et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Opioid receptors in the periaqueductal gray (PAG) con-
tribute to a wide range of behaviors. These include noci-
ceptive modulation, cardiovascular regulation, thermoregu-
lation, and locomotor activity [1–5]. Although mu-opioid
receptors (MOR) are known to contribute to PAG mediated
antinociception [6, 7], less is known about the contribution
of delta-opioid receptors (DORs). Although antinociception
has been produced by the administration of DOR agonists
into the PAG, these eﬀects are mild compared to the
antinociception produced by MOR agonists [8–10].
DORs are particularly interesting because the expression
ofthesereceptorsissurprisinglydynamic.Chronictreatment
with morphine causes the spinal density of DORs to shift
from the cytoplasm to the plasma membrane [11, 12].
A similar shift in DORs from the cytoplasm [13] to the
plasma membrane appears to occur in the PAG. Swim stress
causes an increase in DOR density in the plasma membrane
of PAG neurons [14]. In vitro recordings show that DOR
agonists do not alter GABAergic synaptic transmission in
PAG neurons from drug-naive animals [15–17], but inhibit
GABAergic IPSCs in mice treated chronically with morphine
[18].
The behavioral signiﬁcance of enhanced DOR expression
in the PAG has not been characterized. The increased expres-
sion of DOR in the PAG of morphine tolerant rats could be a
compensatory mechanism for the loss of antinociception at
the mu-opioid receptor. Increased expression of DORs in the
spinal cord has been shown to enhance the antinociceptive
eﬀect of intrathecal administration of the DOR agonist
deltorphin II [19].
The objective of the present study was to determine
the behavioral consequences of activating DORs in the
PAG following induction of morphine tolerance. Given
the widespread eﬀects mediated by the PAG, mobilization
of DORs to the plasma membrane could contribute to
a wide range of behaviors. The enhanced antinociceptive
eﬀects of DOR agonists at the spinal level [19]s u g g e s t
that the administration of DOR agonists into the vPAG of
morphine tolerant rats will produce antinociception. This
hypothesis will be tested by examining the antinociceptive
and locomotor eﬀects of microinjecting the DOR agonist
deltorphin into the vPAG of rats made tolerant to morphine.2 Neural Plasticity
2. Methods
Male Sprague-Dawley rats (240–360g) were anesthetized
with pentobarbital and implanted with a guide cannula
aimed at the ventrolateral PAG using stereotaxic tech-
niques (from lambda: AP = +1.2mm, ML = 0.6mm, and
DV = −4.6mm). The guide cannula was 9mm long and
aﬃxed to two screws in the skull with dental cement.
Rats were handled daily for one week following surgery.
All injections and testing were conducted during the dark
phase of a 12-hour light/dark cycle in a dimly illuminated
room. Experiments were conducted in accordance with the
National Institutes of Health Guide for the Care and Use
of Laboratory animals. Eﬀorts were made to minimize the
number and potential suﬀering of the experimental subjects.
2.1. Materials. Nociception was assessed using the hot plate,
tail withdrawal, and formalin tests. The hot-plate test (IITC,
Woodland Hills, Calif, USA) consisted of measuring the
latency for a rat to lick a hind paw when placed on a 52◦C
plate. Tail withdrawal measured the latency to move the
tail when placed in 52◦C water. The formalin test consisted
of rating pain behavior on a 0–3 scale following injection
of formalin (2% in 50ul) into the plantar surface of the
hind paw [20]. The values on this scale are 0 = normal
behavior; 1 = paw touches the ground without bearing
weight;2 = pawdoesnottouchtheground;3 = pawisabove
the ground and licked.
2.2. Microinjection Procedure. Four days after surgery, an
injection cannula was inserted through the guide cannula,
but no drug was injected. This process habituates rats to
the injection procedure and diminishes behavioral eﬀects
produced by cell damage on the test day. Testing began
one week following surgery, deltorphin II (1μg/0.5μl) or
saline was microinjected into the vPAG. An 11mm injection
cannula was inserted into the guide cannula while the
rat was gently restrained by hand. The injection cannula
extended 2mm beyond the end of the guide cannula. Drugs
were injected at a rate of 0.1ul/10s. The injection cannula
remainedinplaceanadditional20secondstominimizedrug
ﬂow up the cannula track. The stylet was reinserted into the
guide cannula and the rat was returned to its home cage.
Experiment 1. Repeated Morphine Injections. The objective
of this experiment was to determine the behavioral eﬀects
of microinjecting deltorphin into the vPAG in rats made
tolerant to repeated subcutaneous injections of morphine.
Morphine (5, 10, or 20mg/kg) or saline (1ml/kg) was
administered twice a day (at 9:30 and 15:00) for 3.5 days.
Nociception was assessed with the hot plate and tail ﬂick
tests 30 minutes after the injection on trials 1 and 7, but not
after injections on trials 2–6. This procedure limits changes
in nociception from repeated testing [21, 22]. Six hours
after the last subcutaneous injection, all rats were injected
with deltorphin (1μg/0.5μl) into the vPAG. Nociception was
assessed using the hot-plate test 20 minutes later. A subset of
these rats was tested again on the hot plate 50 minutes after
deltorphin administration (N = 9, 5, 10, and 8 for groups
tested with saline, 5, 10, and 20mg/kg of morphine, resp.).
Nociception was assessed using the formalin test in the other
rats (N = 8, 6, and 9 for groups tested with saline, 10, and
20mg/kg of morphine, resp.).
Locomotor activity was assessed for 30 minutes begin-
ning immediately after the 20 minutes hot-plate test.
Activity was assessed by placing the rat into a chamber
(25.1 × 47cm) with 7 photobeams spaced 5.1cm apart (San
Diego Instruments, San Diego, Calif, USA). The average
numberofphotobeamsdisruptedeachminutewasmeasured
and averaged over 10 minute intervals for 30 minutes. The
behavior of the rat was examined every 5 minutes during
the locomotor test in an attempt to determine the reason
for the changes in locomotion (e.g., grooming, sleeping, and
freezing). Normal behavior was deﬁned as walking, sniﬃng,
and grooming.
Experiment 2. Continuous Morphine Administration. Rats
were surgically implanted with a guide cannula aimed at the
vPAGasdescribedinExperiment1.Oneweeklater,tolerance
was induced by implanting two 75mg morphine pellets
under the skin of the upper back while rats were brieﬂy
anesthetized with halothane. Control rats were implanted
with two placebo pellets. Nociception was assessed using the
hot-plate test 2 hours following pellet implantation.
Rats were returned to the test room 3 days after pellet
implantation and allowed to habituate for 30 minutes.
Nociception was assessed at the end of this period using the
hot-plate test to determine whether tolerance had developed.
Following this baseline test, both morphine and placebo-
treated rats were injected with deltorphin (1ug/0.5ul) into
the vPAG. Rats were returned to their cage immediately
following the injection. Nociception was assessed using
the hot-plate test 30 and 60 minutes after the deltorphin
microinjection.
2.3. Histology. Following testing, rats were given an overdose
of halothane (Sigma, St. Louis, Mo, USA). The microinjec-
tion site was marked by injecting cresyl violet (0.2μl) into
the PAG. The brain was removed, placed in formalin (10%),
sectioned coronally (50μm), and viewed under a microscope
to localize the injection site [23]. Only rats with injection
sites in or immediately adjacent to the vPAG were included
in data analysis.
2.4. Data Analysis. The eﬀects of morphine pretreatment
were compared to saline or placebo-treated controls using a
t-test or analysis of variance. The Bonferroni and Tukey tests
were used for post hoc comparisons. Statistical signiﬁcance
was deﬁned as a probability of less than .05.
3. Results
Experiment 1. Repeated Morphine Injections. Systemic ad-
ministrationofhighdosesofmorphine(5,10,and20mg/kg)
produced maximal antinociception on trial 1 (see Figure 1).
A signiﬁcant decrease in antinociception was evident withNeural Plasticity 3
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Figure 1: Tolerance to antinociception develops with repeated
injections of morphine. The hot-plate latency following morphine
administration on trial 7 was signiﬁcantly less than on trial
1 for the morphine-treated groups (F(1, 39) = 31.38, P < .01).
Antinociception was still evident with the administration of large
doses of morphine (10 and 20mg/kg), but not as pronounced as
on trial 1. Large sample sizes were used for most groups (N = 19,
5, 19, and 17 for rats pretreated with saline and morphine at 5, 10,
and20mg/kg,resp.)becausesubsetsoftheseratsweresubsequently
tested using either the formalin test or repeated hot-plate tests.
repeated administration from trial 1 to 7 (F(1,56) = 53.446,
P < .05). The magnitude of the decrease in antinociception
was dose dependent (F(3,56) = 5.536, P < .05). That is, the
lowest dose (5mg/kg) produced the least antinociception
and the highest dose (20mg/kg) produced the greatest
antinociception in morphine tolerant rats.
Microinjection of deltorphin into the vPAG of morphine
naiveratsproducedaslightincreaseinhot-platelatency.Rats
pretreated with saline showed a signiﬁcant increase in hot-
plate latency following microinjection of deltorphin from
1 0 . 8( s e et r i a l7i nFigure 1) to 14.5 seconds (20-minute test
in Figure 2) (one-tailed t(18) = 1.925, P < .05).
The eﬀect of microinjecting deltorphin into the vPAG
of morphine tolerant rats varied with the pretreatment
dose (see Figure 2). A 2 × 2 ANOVA revealed a signiﬁcant
diﬀerence in hot-plate latency between the pretreatment
groups (F(3,84) = 3.203, P < .05), but no diﬀerence in
hot-plate latency between the 20- and 50-minute tests
(F(1,84) = 0.866; P > .05). The diﬀerence between groups
was caused by a slight increase in the hot-plate latency
of rats pretreated with 20mg/kg of morphine and a slight
decrease in latency in rats pretreated with 10mg/kg (see
Figure 2). Although the diﬀerence between these groups
was statistically signiﬁcant (Bonferroni, t = 2.420, P < .05),
neither the 10mg/kg (t = 0.96 and 1.15 for 20 and 50
minutes, resp.) nor the 20mg/kg (t = 1.49 and 0.87 for
20 and 50 minutes, resp.) groups diﬀered from the saline-
pretreated group. Moreover, these changes in nociception
were quite small compared to the antinociception produced
by systemic administration of morphine on trial 7 (26.2±2.7
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Figure 2: Changes in nociception following microinjection of
deltorphin into the vPAG. Nociception was assessed 20 and 50
minutes after deltorphin microinjection into the vPAG of rats made
tolerant to morphine. Pretreatment with morphine produced a
slightdecreaseinhot-platelatencyinratsmadetolerantto10mg/kg
of morphine compared to the slight increase in rats made tolerant
to20mg/kgofmorphine,althoughneitherofthesechangesdiﬀered
signiﬁcantly from the eﬀects of deltorphin administration in saline-
pretreated controls. All rats were tested on the hot plate 20 minutes
after deltorphin microinjection (see sample sizes in the caption of
Figure 1), but only a subset was tested at 50 minutes for the saline
(N = 9), 5 (N = 5), 10 (N = 10), and 20 (N = 8)mg/kg morphine
groups.
and 31.3 ± 2.7 seconds following 10 and 20mg/kg doses of
morphine).
A similar diﬀerence between pretreatment groups was
evident when nociception was assessed with the tail ﬂick test
50minutesafterdeltorphinadministration(F(2,52) = 8.699,
P < .05). Microinjection of deltorphin into the PAG of rats
pretreated with 20mg/kg of morphine caused a small, but
signiﬁcant, increase in tail ﬂick latency (4.4 ± 0.2 seconds)
compared to rats pretreated with saline (3.5 ± 0.2 seconds)
or 10mg/kg of morphine (3.4 ± 0.2 seconds) (Tukey test,
P < .05 for both comparisons).
Nociception was assessed using the formalin test in the
rats not tested on the hot plate at 50 minutes. Formalin was
injected 5 minutes following the 20 minute hot-plate test
so the ﬁrst and second phases [20] could be assessed 25–
29 and 40–44 minutes after microinjection of deltorphin. In
contrast to the hot-plate test, pain ratings on the formalin
test did not diﬀer between the pretreatment groups on
either the ﬁrst (mean ratings = 1.65, 1.60, and 1.73) or
the second (mean ratings = 0.40, 0.63, and 0.67) phases
(F(2,20) = 0.272, P = .76).
Locomotor activity was assessed during the 30 minutes
following the 20 minute hot-plate test in the subset of rats
not injected with formalin. Microinjection of deltorphin
into the vPAG caused a signiﬁcant decrease in activity
in the morphine compared to the saline-pretreated rats
(F(2,29) = 6.84, P < .05). This decrease was similar in rats4 Neural Plasticity
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Figure 3: Decrease in locomotion following microinjection of
deltorphinintothevPAG.Microinjectionofdeltorphin(1μg/0.5μl)
into the vPAG caused a decrease in locomotion in rats pretreated
with morphine (N = 13 and 9 for rats pretreated with 10 and
20mg/kg) compared to rats pretreated with saline (N = 11). This
decreaseinactivityiscausedbyachangeinnormalbehaviortolying
and crouching in the cage following deltorphin administration (see
Table 1).
Table 1:Percentage ofratsshowingnormalandabnormalbehavior
following deltorphin microinjection into the vPAG in morphine-
pretreated rats.
Crouching/lying
Pretreatment 25–39 minutes 40–54 minutes
Saline 0% (0/6) 0% (0/6)
Morphine 10mg 20% (1/5) 67% (6/9)
Morphine 20mg 36% (4/11) 40% (6/15)
Note: sample sizes are shown in parentheses.
pretreated with 10 and 20mg/kg of morphine (see Figure 3).
The greatest decrease in activity was evident at the latest time
period (41–50 minutes) for both pretreatment groups.
The decrease in activity was accompanied by a change
in behavior in which rats tended to crouch or lie down
in the activity chamber. An increase in the number of rats
crouching or lying increased in rats pretreated with 10 and
20mg/kg of morphine beginning approximately 25 minutes
afterthedeltorphinmicroinjection(seeTable 1).Thisshiftin
the number of rats displaying normal exploratory behavior
to crouching and lying increased further during the last
15 minutes of the test (40–54 minutes after the deltorphin
microinjection).
Experiment 2. Continuous Morphine Administration. Im-
plantation of morphine pellets produced an increase in
hot-plate latency compared to placebo-treated rats when
assessed at 1 hour (36.1 ± 3.9v e r s u s2 0 .5 ± 2.4 seconds;
t(8) = 3.865,P < .05).Tolerancetotheantinociceptiveeﬀect
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Figure 4: No change in nociception following deltorphin microin-
jection into the vPAG in rats treated with continuous morphine.
Rats implanted with morphine pellets 3 days prior to this test had
higher baseline hot-plate latency than rats implanted with placebo
pellets indicating that tolerance to the antinociceptive eﬀects was
not complete. Microinjection of deltorphin into the vPAG caused
an increase in hot-plate latency in rats with placebo pellets (N = 5),
but did not increase the hot-plate latency for rats with morphine
pellets (N = 5) above the baseline latency. That is, there was no
additional antinociception by injecting deltorphin into the vPAG of
rats receiving morphine.
of morphine was evident by day 4 as indicated by a decrease
in hot-plate latency to 18.8 ± 1.8 seconds. Microinjection of
deltorphin into the PAG caused a modest, but signiﬁcant,
increase in hot-plate latency compared to baseline latency
(F(2,16) = 5.806, P < .05). Although the baseline hot-plate
latency for rats treated with morphine pellets was greater
than in placebo-treated rats (see Figure 4), this diﬀerence
did not reach statistical signiﬁcance using the Bonferroni
test (t = 1.482 nanoseconds). However, microinjection of
deltorphin into the vPAG of placebo-treated rats caused a
signiﬁcant increase in hot-plate latency at the 60-minute
time point compared to the baseline (Bonferroni, t = 3.044.
P < .05). There was no diﬀerence in mean hot-plate latency
following deltorphin administration between morphine and
placebo-treated rats (F(1,8) = 0.791, P > .05), suggesting
that deltorphin administration did not increase antinocicep-
tion beyond what was already present in rats with morphine
pellets.
4. Discussion
The present data demonstrate that repeated morphine
administration alters the response of vPAG neurons to the
DOR agonist deltorphin. Although PAG neurons contribute
to a wide range of behaviors [24], the change in response to
deltorphin microinjection was speciﬁc to locomotor activity.
Microinjection of deltorphin into the vPAG produced a con-
sistent decrease in activity in rats pretreated with morphine.Neural Plasticity 5
This decrease in activity was caused by a drastic change in
behavior from exploring and grooming to crouching and
lying along the edge of the cage. In contrast, microinjection
of deltorphin produced a mild antinociception that was
not altered in a consistent manner by prior morphine
administration.
MOR agonists such as morphine are the most eﬀective
treatment for pain. The descending modulatory system
that runs from the PAG to rostral ventromedial medulla
(RVM) to spinal dorsal horn plays an important role in
the antinociceptive eﬀects of both MOR and DOR agonists
[9, 25–28]. The antinociception produced by microinjection
ofDORagonistsintothePAGisweakcomparedtomorphine
administration [9, 10]. However, DORs are located in the
PAG [13] and these receptors appear to move from the
cytoplasm to the plasma membrane following stress [14].
The density of DORs on the membrane has also been shown
to increase in spinal neurons following chronic exposure to
morphine [11, 12].
The present data show that microinjection of deltorphin
into the vPAG had modest eﬀects on nociception. Rats
pretreated with 10mg/kg of morphine showed a slight
hyperalgesiacompared to saline-pretreated ratsinjected with
deltorphin into the vPAG. This eﬀect seems to be dose and
test dependent. Rats pretreated with 20mg/kg of morphine
showed a slight increase in hot-plate latency following
deltorphin microinjection. No changes in nociception were
evident on the formalin test. The lack of eﬀect of deltorphin
in modulating nociception is surprising given that spinal
administration of deltorphin following chronic morphine
administration produces antinociception [11].
The lack of a consistent change in nociception following
deltorphin administration could be caused by an inability of
themorphineadministrationproceduretomobilizeDORsto
the plasma membrane. Although possible, this explanation
seems unlikely given that a decrease in activity was produced
by microinjection of deltorphin into the PAG. Moreover, we
used two diﬀerent procedures to induce tolerance (repeated
injectionsandcontinuousadministration)thatcloselymatch
previous studies reporting changes in DORs [11, 12, 18].
Finally, mobilization of DORs to the plasma membrane
is associated with morphine tolerance and the rats in
the present study showed clear signs of tolerance to the
antinociceptive eﬀects of morphine.
In vitro electrophysiological recordings reveal DOR-
mediated inhibition of GABAergic IPSCs in tissue from
mice pretreated with morphine [18], but no eﬀect of DOR
agonists in PAG slices from animals that have not been
exposed to morphine [15–17]. This inhibition of GABA
input is similar to the eﬀect produced by administration of
MOR agonists into the PAG [29]. These data suggest that
microinjection of DOR agonists into the PAG of morphine
tolerant rats should produce antinociception. However, the
present data show no consistent antinociceptive eﬀect fol-
lowing deltorphin microinjection into the PAG of morphine
tolerant rats.
In contrast, microinjection of deltorphin into the vPAG
of morphine pretreated-rats caused a clear and consistent
decrease in locomotor activity. Acute administration of
morphine into the vPAG also produces a decrease in
activity [4]. Thus, it appears that DORs compensate for the
locomotor,butnottheantinociceptiveeﬀectsassociatedwith
morphine tolerance in the vPAG. The immobility produced
by morphine microinjection into the vPAG appears to be
part of a defensive freezing response [30–33]. However, the
decreaseinactivityproducedbymicroinjectionofdeltorphin
into the vPAG reported here does not appear to be caused by
fear-induced freezing. Microinjection of deltorphin caused
rats to crouch and lay along the edge of the cage as if the rats
wereillordysphoric.Thiseﬀectappearstobeconsistentwith
previous research showing that deep tissue pain suﬃcient to
induce recuperative behavior activates vPAG neurons [34].
GiventhatstressincreasesthedensityofDORsontheplasma
membrane [14], activation of these receptors may contribute
to recuperative behavior.
One hypothesis is that the recuperative behavior medi-
ated by the vPAG is part of a coordinated response triggered
by severe hemorrhage that includes hypotension. Severe
blood loss has been shown to activate neurons in the vPAG
[35], and inactivation of the vPAG [2, 36] or microinjection
of the DOR antagonist naltrindole into the PAG [37] blocks
thehypotensionproducedbyhemorrhage.Futurestudiesare
needed to determine whether activation of DORs in the PAG
alters blood pressure.
5. Conclusion
The decrease in locomotor activity caused by microinjection
of deltorphin into the vPAG of morphine tolerant rats is
consistent with previous data showing that DOR density on
the plasma membrane increases following chronic morphine
administration. PAG DORs could contribute to morphine
tolerance [38–40], behavioral changes related to stress [14],
or hypovolemic shock [35, 37], but do not appear to
contribute to antinociception. That is microinjection of
deltorphin into the PAG did not produce antinociception
regardless of how tolerance was induced (repeated injections
or continuous administration), test used to assess nocicep-
tion (hot plate, tail ﬂick, and formalin tests), or test times
(20 and 50 minutes).
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